"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 4 | 4 | 8 |
| 2006 | 6 | 6 | 12 |
| 2007 | 7 | 1 | 8 |
| 2008 | 7 | 6 | 13 |
| 2009 | 4 | 4 | 8 |
| 2010 | 10 | 8 | 18 |
| 2011 | 6 | 5 | 11 |
| 2012 | 12 | 10 | 22 |
| 2013 | 9 | 11 | 20 |
| 2014 | 7 | 5 | 12 |
| 2015 | 7 | 4 | 11 |
| 2016 | 10 | 7 | 17 |
| 2017 | 5 | 4 | 9 |
| 2018 | 7 | 3 | 10 |
| 2019 | 9 | 5 | 14 |
| 2020 | 4 | 4 | 8 |
| 2021 | 3 | 6 | 9 |
| 2022 | 3 | 4 | 7 |
| 2023 | 1 | 2 | 3 |
| 2024 | 4 | 1 | 5 |
| 2025 | 7 | 3 | 10 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation. Clin Transl Sci. 2026 04; 19(4):e70537.
-
Local ancestry-informed GWAS of warfarin dose requirement in African Americans identifies a CYP2C19 splicing QTL. Am J Hum Genet. 2025 11 06; 112(11):2708-2719.
-
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clin Pharmacol Ther. 2025 12; 118(6):1430-1436.
-
Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors. Cancer Med. 2025 Sep; 14(17):e71218.
-
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clin Pharmacol Ther. 2026 01; 119(1):109-119.
-
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clin Pharmacol Ther. 2025 10; 118(4):906-916.
-
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. Clin Pharmacol Ther. 2025 Oct; 118(4):778-789.
-
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. JAMA Netw Open. 2025 06 02; 8(6):e2516296.
-
Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study. Support Care Cancer. 2025 Apr 08; 33(5):362.
-
Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing. Clin Transl Sci. 2025 04; 18(4):e70193.